Heat loads and cryogenics for HE-LHC

We report preliminary considerations on cryogenics for a higher-energy LHC ("HE-LHC") with about 16.5 TeV beam energy and 20-T dipole magnets. In particular we sketch the heat loads scaled on the proposed principal beam parameters and size the cryogenic plants for different operating temperature of the beam screens.Comment: 4 pages, contribution to the EuCARD-AccNet-EuroLumi Workshop: The High-Energy Large Hadron Collider, Malta, 14 -- 16 Oct 201

Cryogenics for CERN experiments: past, present and future

Use of cryogenics at CERN was originated (in the 1960s) by bubble chambers and the associated s.c. solenoids. Complex cryoplants were installed to provide cooling at LH2 and LHe temperatures. Continuity (in the 1970s) in He cryogenics for experiments was provided by spectrometer magnets for fixed target physics of the SPS accelerator. More recently (in the 1980s), large "particle-transparent" s.c. solenoids for collider experiments (LEP) have been built demanding new cryoplants. The LHC experiments (in the 2000s) will continue the tradition with s.c. dipoles (ALICE and LHCb), solenoids (CMS, ATLAS) and toroids (ATLAS) of unusual size. Cryogenics for experiments using noble liquids follows the same trend since the development (in the 1970s) of the first shower LAr detectors. A LKr calorimeter (about 10 m3) will be operated in 1996 and the ATLAS experiment foresees a set of three huge LAr calorimeters (almost 90 m3 total volume of liquid) to be installed underground

A study of empyema thoracis and role of intrapleural streptokinase in its management

BACKGROUND: Clinical spectrum, microbiology and outcome of empyema thoracis are changing. Intrapleural instillation of fibrinolytic agents is being increasingly used for management of empyema thoracis. The present study was carried out to describe the clinical profile and outcome of patients with empyema thoracis including those with chronic empyema and to study the efficacy and safety of intrapleural streptokinase in its management. METHODS: Clinical profile, etiological agents, hospital course and outcome of 31 patients (mean age 40 ± 16 years, M: F 25: 6) with empyema thoracis treated from 1998 to 2003 was analyzed. All patients were diagnosed on the basis of aspiration of frank pus from pleural cavity. Clinical profile, response to therapy and outcome were compared between the patients who received intrapleural streptokinase (n = 12) and those who did not (n = 19). RESULTS: Etiology was tubercular in 42% of the patients (n = 13) whereas the rest were bacterial. Amongst the patients in which organisms could be isolated (n = 13, 42%) Staphylococcus aureus was the commonest (n = 5). Intrapleural streptokinase was instilled in 12 patients. This procedure resulted in increase of drainage of pleural fluid in all patients. Mean daily pleural fluid drainage after streptokinase instillation was significantly higher for patients who received intrapleural streptokinase than those who did not (213 ml vs 57 ml, p = 0.006). Only one patient who was instilled streptokinase eventually required decortication, which had to be done in five patients (16.1%). Mean hospital stay was 30.2 ± 17.6 days whereas two patients died. CONCLUSIONS: Tubercular empyema is common in Indian patients. Intrapleural streptokinase appears to be a useful strategy to preserve lung function and reduce need for surgery in patients with late stage of empyema thoracis

CMS physics technical design report : Addendum on high density QCD with heavy ions

Peer reviewe